#USA #California #Securities Fraud #Soleno Therapeutics #SLNO

Soleno Therapeutics, Inc. Faces Class Action Lawsuit Due to Alleged Securities Fraud

In a recent development, Soleno Therapeutics, Inc. (NASDAQ: SLNO) has come under fire for alleged securities fraud. A class action lawsuit has been filed against the company, drawing attention to significant concerns surrounding its product and the integrity of its clinical trials.

Overview of the Situation

The lawsuit targets investors who purchased Soleno's common stock during the period from March 26, 2025, to November 4, 2025. The lead plaintiff for the case must be designated by May 5, 2026. This lawsuit has been filed in the United States District Court for the Northern District of California and is officially titled City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, Inc., under case number 326-cv-01979.

Allegations Against Soleno Therapeutics

The heart of the allegations revolves around claims that the company made materially false statements regarding its Phase 3 clinical trials for its drug, diazoxide choline extended-release tablets (DCCR). The allegations assert that Soleno misrepresented key safety data from their trials, potentially endangering patients and misleading investors. Specific accusations include:
1. Understating Safety Concerns: The complaint suggests that Soleno downplayed safety issues associated with DCCR’s use, particularly concerning excess fluid retention, which raised serious health risks for users.
2. Concealment of Adverse Facts: Allegations indicate that the company failed to disclose serious risks affecting the medication's commercial viability, which would be critical to patients suffering from Prader-Willi syndrome (PWS), the primary condition DCCR is designed to treat.
3. Impact on Stock Value: Following the release of a critical report by Scorpion Capital on August 15, 2025, concerning the company's clinical trials, Soleno’s stock fell significantly—dropping over 26%. This report highlighted numerous deficiencies in the trial protocols, causing increased anxiety within the PWS community and leading to reduced patient enrollment in the treatment program.

What Affected Investors Should Do

For investors affected by these developments, the firm Kessler Topaz Meltzer & Check, LLP (KTMC) has provided an avenue for recovery. They encourage those who invested in Soleno during the specified period and experienced losses to reach out for a free consultation. Investors can consider filing for lead plaintiff status by the deadline and assess if they wish to join the class action.

Legal Representation and Next Steps

Investor actions can include:

• - Filing for Lead Plaintiff Status: Interested investors must act promptly before the stated deadline to take on a leadership role in the litigation process.
• - Seeking Legal Counsel: KTMC offers no-cost evaluations for potential cases and operates on a contingency fee basis, meaning investors don’t pay unless there is a recovery.
• - Understanding the Representation Process: The process for becoming a lead plaintiff involves selecting representatives who can effectively manage the case and advocate for the collective interests of all affected investors.

Conclusion

The legal issues currently facing Soleno Therapeutics spotlight the broader implications of corporate responsibility in the pharmaceutical industry. With healthcare products, transparency regarding safety and efficacy is paramount, and investors must remain vigilant about the companies in which they place their trust and resources. As this class action lawsuit unfolds, it will remain to be seen how Soleno reclaims investor confidence, if at all. Those impacted should stay informed and reach out to legal experts to explore recovery options.

For those interested in participating in this case or exploring further details, visiting the KTMC website may provide additional resources and insights.